Compare · MAZE vs MRNA
MAZE vs MRNA
Side-by-side comparison of Maze Therapeutics Inc. (MAZE) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MAZE and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.25B, about 13.9x MAZE ($1.31B).
- Over the past year, MAZE is up 85.0% and MRNA is up 65.6% - MAZE leads by 19.3 points.
- MAZE has been more active in the news (16 items in the past 4 weeks vs 15 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- Maze Therapeutics Inc.
- Moderna Inc.
- Price
- $23.67-1.02%
- $46.00-3.65%
- Market cap
- $1.31B
- $18.25B
- 1M return
- -7.18%
- -13.04%
- 1Y return
- +84.99%
- +65.65%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 16
- 15
- Recent ratings
- 7
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MAZE
- SEC Form 4 filed by Director Spiegelman Daniel K
- SEC Form 4 filed by Director Scheller Richard H
- SEC Form 4 filed by Director Lim Jonathan E
- SEC Form 4 filed by Director Hoppenot Herve
- SEC Form 4 filed by Director Homcy Charles J
- SEC Form 4 filed by Director Andrews Nancy C
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Chief Executive Officer Coloma Jason V sold $174,048 worth of shares (6,643 units at $26.20) as part of a pre-agreed trading plan (SEC Form 4)
- President, R&D & CMO Bernstein Harold sold $381,112 worth of shares (14,853 units at $25.66) as part of a pre-agreed trading plan and exercised 14,853 shares at a strike of $10.42 (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $197,554 worth of shares (7,500 units at $26.34) as part of a pre-agreed trading plan (SEC Form 4)
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability